Filing Flows › Cytosorbents (CTSO) › Q1 2026
Cytosorbents (CTSO) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 13, 2026
Cytosorbents (CTSO) reported revenue of $8.9M for the first quarter 2026 (Q1 2026), +2% from a year earlier and -4% from the quarter before. Operating margin was -34.3%, net loss $5.1M (57.9% of revenue).
Cytosorbents, Q1 2026: revenue $8.9M (+2% year over year), operating margin -34.3%, net loss $5.1M, operating cash flow −$1.2M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.9M | -4% | +2% |
| Operating profit | −$3.0M | — | — |
| Net earnings | −$5.1M | — | — |
| Operating cash flow | −$1.2M | — | — |
What changed
Revenue was $8.9M in Q1 2026, up 2% year over year and down 4% from the previous quarter.
Gross margin was 69.2%, down 2.0 points from Q1 2025. Operating costs exceeded revenue by $3.0M, an operating margin of -34.3%. Operating expenses fell 9% while revenue rose 2%. The quarter ended with a net loss of $5.1M, narrower than the previous quarter's $5.5M loss.
Operating cash flow was −$1.2M. Non-cash charges added back $350K of depreciation and amortization and $544K of share-based compensation. Working capital and other items added $3.1M. Capital expenditures of $11K exceeded it, leaving free cash flow of −$1.2M.
Questions
What was Cytosorbents' revenue in the first quarter 2026?
Cytosorbents (CTSO) reported revenue of $8.9M for the first quarter 2026 (Q1 2026), +2% from a year earlier and -4% from the quarter before.
Was Cytosorbents profitable in the first quarter 2026?
Operating loss was $3.0M (-34.3% of revenue) and net loss $5.1M.
Source: Cytosorbents 10-Q on SEC EDGAR.